Sabur Natasha F, Esmail Aliasgar, Brar Mantaj S, Dheda Keertan
Lung Infection and Immunity Unit, Division of Pulmonology and University of Cape Town Lung Institute, Department of Medicine, University of Cape Town, H47 Old Main Building, Groote Schuur Hospital, Observatory, Cape Town, 7925, South Africa.
Division of Respirology, Department of Medicine, St. Michael's Hospital and West Park Healthcare Centre, University of Toronto, Toronto, Canada.
BMC Infect Dis. 2017 Dec 28;17(1):803. doi: 10.1186/s12879-017-2914-7.
Up to one third of HIV-infected individuals with suspected TB are sputum-scarce. The Alere Determine™ TB LAM Ag lateral flow strip test can be used to diagnose TB in HIV-infected patients with advanced immunosuppression. However, how urine LAM testing should be incorporated into testing algorithms and in the context of specific patient sub-groups remains unclear.
This study represents a post hoc sub-group analysis of data from a randomized multi-center parent study. The study population consisted of hospitalized HIV-infected patients with suspected TB who were unable to produce sputum and who underwent urine LAM testing. The diagnostic utility of urine LAM for TB in this group was compared to the performance of urine LAM in patients who did produce a sputum sample in the parent study.
There were a total of 187 and 2341 patients in the sputum-scarce and sputum-producing cohorts, respectively. 80 of the sputum-scarce patients underwent testing with urine LAM. In comparison to those who did produce sputum, sputum-scarce patients had a younger age, a lower Karnofsky performance score, and a lower weight and BMI at admission. A greater proportion of sputum-scarce patients were urine LAM positive, compared to those who were able to produce sputum (31% vs. 21%, p = 0.04). A higher proportion of sputum-scarce patients died within 8 weeks of admission (32% vs. 24%, p = 0.013). We inferred that 19% of HIV-infected sputum-scarce patients suspected of TB were diagnosed with tuberculosis by urine LAM testing, with an estimated positive predictive value of 63% (95% CI 43-82%).
Urine LAM testing can effectively identify tuberculosis in HIV-infected patients who are at a higher risk of mortality yet are unable to generate a sputum sample for diagnostic testing. Our findings support the use of urine LAM testing in sputum-scarce hospitalized HIV-infected patients, and its incorporation into diagnostic algorithms for this patient population.
多达三分之一疑似结核病的HIV感染者痰液稀少。Alere Determine™结核分枝杆菌脂阿拉伯甘露聚糖(TB LAM)抗原侧向流动试纸条检测可用于诊断免疫抑制严重的HIV感染患者的结核病。然而,尿液LAM检测应如何纳入检测算法以及在特定患者亚组的背景下如何应用仍不明确。
本研究是一项对随机多中心母研究数据的事后亚组分析。研究人群包括因疑似结核病住院且无法咳痰并接受尿液LAM检测的HIV感染患者。将该组中尿液LAM对结核病的诊断效用与母研究中能够咳出痰样本的患者的尿液LAM检测性能进行比较。
痰液稀少组和咳痰组分别共有187例和2341例患者。80例痰液稀少的患者接受了尿液LAM检测。与能够咳痰的患者相比,痰液稀少的患者年龄更小,卡氏评分更低,入院时体重和体重指数更低。与能够咳痰的患者相比,痰液稀少的患者尿液LAM阳性比例更高(31%对21%,p = 0.04)。痰液稀少的患者在入院8周内死亡的比例更高(32%对24%,p = 0.013)。我们推断,19%疑似结核病的HIV感染痰液稀少患者通过尿液LAM检测被诊断为结核病,估计阳性预测值为63%(95%CI 43 - 82%)。
尿液LAM检测可有效识别有较高死亡风险但无法咳出痰样本进行诊断检测的HIV感染患者的结核病。我们的研究结果支持在痰液稀少的住院HIV感染患者中使用尿液LAM检测,并将其纳入该患者群体的诊断算法。